FibroGen Inc (NASDAQ:FGEN) – Svb Leerink boosted their FY2020 EPS estimates for shares of FibroGen in a report released on Monday, November 11th. Svb Leerink analyst G. Porges now expects that the biopharmaceutical company will post earnings of $1.43 per share for the year, up from their prior forecast of $1.41.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.02. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The company had revenue of $33.17 million during the quarter, compared to the consensus estimate of $31.61 million. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. FibroGen’s revenue for the quarter was up 14.3% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the stock. Mizuho reiterated a “positive” rating and set a $72.00 target price (up previously from $65.00) on shares of FibroGen in a research note on Monday. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research note on Tuesday, August 13th. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, TheStreet upgraded shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $58.33.

Shares of FGEN opened at $34.58 on Tuesday. FibroGen has a fifty-two week low of $32.33 and a fifty-two week high of $61.23. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -33.57 and a beta of 1.84. The firm has a 50-day simple moving average of $38.39 and a 200-day simple moving average of $41.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.73.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors purchased a new position in FibroGen during the second quarter worth about $90,000. US Bancorp DE raised its holdings in FibroGen by 79.7% during the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 963 shares in the last quarter. Usca Ria LLC purchased a new position in FibroGen during the third quarter worth about $123,000. Convergence Investment Partners LLC purchased a new position in FibroGen during the third quarter worth about $137,000. Finally, Nisa Investment Advisors LLC raised its holdings in FibroGen by 729.8% during the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,430 shares in the last quarter. 69.03% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the completion of the sale, the chief executive officer now owns 2,356,578 shares in the company, valued at $104,467,102.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Pat Cotroneo sold 3,201 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $41.38, for a total transaction of $132,457.38. Following the sale, the chief financial officer now owns 244,432 shares of the company’s stock, valued at approximately $10,114,596.16. The disclosure for this sale can be found here. Insiders have sold 86,756 shares of company stock valued at $3,644,083 in the last quarter. Insiders own 7.83% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: Short Selling Stocks and Day Traders

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.